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ABSTRACT
As genes for inherited disease are increasingly well characterized by next generation sequencing approaches, it is clear that some mutations may act through promoters, enhancers, and other non-coding regulatory regions. Our hypothesis for this proposal is that much of the substantial remaining familial risk of breast cancer is due to a large number of individually rare alleles of moderate-to-severe effect located in the non-coding regions of the genome. For this proposal we will evaluate 30 large, extended kindreds severely affected with breast cancer, each of whom has been comprehensively evaluated in our lab by targeted genomic sequencing for mutations of all classes in all known breast cancer genes and by whole exome sequencing for coding region mutations exome-wide. These families are a unique discovery series for identification of regulatory mutations that may reveal new mutational mechanisms for breast cancer predisposition. SPECIAL REPORTING REQUIREMENTS 9 APPENDICES 9-10 1. INTRODUCTION: Despite tremendous advances in mutation detection with gene panels and exome sequencing, most families severely affected by breast cancer do not have causative alleles identified from the protein-coding region of the genome. We hypothesize that the causal mutations in many of these families lie in uncharacterized regulatory regions of the genome. Through whole genome sequence analysis of severely affected families and functional annotation and experimental evidence, we undertook to identify new mutational mechanisms that predispose to breast cancer. Our ultimate goal is to enable information on newly identified mutations and mutational mechanisms to be useful to clinicians and to women and their families.
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ACCOMPLISHMENTS:
What were the major goals of the project?
The major goals of this project as stated in the approved SOW are listed below: 
All components of TASK 4 have been completed
What was accomplished under these goals?
TASK 1: (Walsh) We prepared both library types and generated whole genome sequencing data on the 100 breast cancer patients. We obtained median sequence coverage of 34X, with 99.89% of basepairs read at least 8 times. Figure 1 below illustrates the distribution of read depths across the 100 samples and Figure 2 shows the distribution of median read depths. 
Number of samples
Median read depth TASK 2: (Walsh) In Year 2 after sequencing was completed, we developed a functional annotation approach to filter variants from the whole genome sequences. Sequence reads from TASK1 were aligned to the genome with BWA 1 which is presently the preferred alignment tool of the genomics community. Single nucleotide variants (SNVs) and small indels (1-50bp) we identified by GATK 2 , UnifiedGenotyper 3 , FreeBayes 4 and Samtools 5 . Structural Variants (SVs) greater than 500bp were identified with Lumpy 6 , SVtyper 7 and CNVnator 8 . We felt it was important to use all these calling tools since they have different specificities and sensitivities.
In order to remove common and likely benign SNPs, indels and SVs for follow up in TASK3 we filtered using these criteria:
(i) Less than 1% frequency in the 1000 Genomes Project 9 and Genomes of the Netherlands 10 (ii) Present in less than 4 of the breast cancer families that we sequenced in TASK1 (iii) Variant read proportion greater than 0.25 (iv) Read depth greater than 8 in at least one sample
The Table below shows variant data from Family 1041 categorized by functional effect. In order to prioritize SNPs, indels and SVs for follow up in TASK3 we filtered remaining variants by segregation in each family. We excluded any variant that was not present in at least three women with breast cancer in a family.
The remaining variants were annotated for regulatory potential as follows:
1. ENCODE regions 11 : We used chromatin predictions from Human Mammary Epithelial cell lines (DNaseI and H3K27Ac signals). In addition, transcription factor CHiP-seq and DNaseI clusters from 7 breast cancer cell lines and finally predicted Transcription Factor binding motifs.
2. Potential motif disruption: For each potential ENCODE region and overlapping Transcription Factor binding motifs, we calculated motif score changes using position weight matrices 3. Non coding prediction: We used scores generated by DANN 12 , FATHMM 13 and FunSeq2 14 that combine population frequencies and nucleotide conservation for non-coding regions of the genome.
At the end of TASK 2 we selected 112 non-coding variants from the 33 breast cancer families that shared these features:
(i) segregated with breast cancer in a family (ii) private or ultra-rare in population databases (iii) predicted to disrupt a potential regulatory element (iv) within 2MB of a known breast cancer predisposition gene TASKS 3 and 4 were performed in Year 2.
TASK 3. (King) We assessed gene expression levels by RT-PCR and targeted RNAseq using RNA from freshly acquired blood samples of the 33 patients harboring the 112 variants described in TASK 2. Of the 112 variants evaluated 11 showed expression profiles suggesting dysregulation of gene transcription.
TASK 4. (King) We genotyped the 11 variants from TASK3 in 960 female cancer free controls and 960 unrelated breast cancer patients different from those used in TASK1. We did not observe these variants in any of the 960 controls or in any other familial breast cancer cases confirming they are rare or potentially private to their host families.
We also sequenced approximately 300bp around each of the 11 variants of interest in 960 female cancer-free controls and 960 unrelated breast cancer patients. There were no additional rare variants that were predicted to disrupt a regulatory element.
What opportunities for training and professional development has the project provided?
Nothing to report
How were the results disseminated to communities of interest?
We are in the process of writing two manuscripts describing:
(i) Our approach for targeted RNA sequencing to evaluate non-coding variants (ii)
Our bioinformatics analysis of family based whole genome sequencing data Our main findings describing the 11 interesting non-coding variants will require additional confirmation before publishing and presentation at scientific meetings.
What do you plan to do during the next reporting period to accomplish the goals?
Nothing to report (end of this project)
IMPACT
What was the impact on the development of the principal discipline(s) of the project?
Our approach integrated whole genome sequencing with experimental biology and with application and development of bioinformatics tools to discover regulatory variants that may predispose women to develop breast cancer. Through our publications and data we hope that this approach will encourage other researchers to examine non-coding portions of the genome for additional cancer predisposing mutations.
What was the impact in other disciplines? Nothing to report
What was the impact on technology transfer? Nothing to report
What was the impact on society beyond the science and technology?
Through our publications and data we hope that non-coding variants that definitely impact breast cancer gene expression will be incorporated into clinical care. 
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